Malignant peripheral nerve sheath tumor historical perspective: Difference between revisions
Marjan Khan (talk | contribs) No edit summary |
Marjan Khan (talk | contribs) |
||
| (7 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
NF1-like cutaneous tumor syndromes appeared in the literature in 1880s, when Friedrich von Recklinghausen published seminal observations detailing cutaneous tumors comprised of both neuronal and fibroblastic tissue finally termed as neurofibromas. In 2006, Yang et al demonstrated a critical neurofibroma microenvironment interaction that includes SCF-stimulated Nf1+/− mast cells potentiating Nf1+/− fibroblast functions. | |||
==Historical Perspective== | |||
*In 18th century, NF1-like cutaneous tumor syndromes appeared in the literature. <ref name="pmid10190829">{{cite journal| author=Morse RP| title=Neurofibromatosis type 1. | journal=Arch Neurol | year= 1999 | volume= 56 | issue= 3 | pages= 364-5 | pmid=10190829 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10190829 }} </ref> | |||
*In 1880s, Friedrich von Recklinghausen published seminal observations detailing cutaneous tumors comprised of both neuronal and fibroblastic tissue finally termed as neurofibromas. | |||
*In 2006, Yang et al demonstrated a critical neurofibroma microenvironment interaction that includes SCF-stimulated Nf1+/− mast cells potentiating Nf1+/− fibroblast functions. <ref>http://www.bloodjournal.org/content/116/2/157?sso-checked=true</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 13:33, 16 August 2019
|
Malignant peripheral nerve sheath tumor Microchapters |
|
Differentiating Malignant Peripheral Nerve Sheath Tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Malignant peripheral nerve sheath tumor historical perspective On the Web |
|
American Roentgen Ray Society Images of Malignant peripheral nerve sheath tumor historical perspective |
|
FDA on Malignant peripheral nerve sheath tumor historical perspective |
|
CDC on Malignant peripheral nerve sheath tumor historical perspective |
|
Malignant peripheral nerve sheath tumor historical perspective in the news |
|
Blogs on Malignant peripheral nerve sheath tumor historical perspective |
|
Directions to Hospitals Treating Malignant peripheral nerve sheath tumor |
|
Risk calculators and risk factors for Malignant peripheral nerve sheath tumor historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]
Overview
NF1-like cutaneous tumor syndromes appeared in the literature in 1880s, when Friedrich von Recklinghausen published seminal observations detailing cutaneous tumors comprised of both neuronal and fibroblastic tissue finally termed as neurofibromas. In 2006, Yang et al demonstrated a critical neurofibroma microenvironment interaction that includes SCF-stimulated Nf1+/− mast cells potentiating Nf1+/− fibroblast functions.
Historical Perspective
- In 18th century, NF1-like cutaneous tumor syndromes appeared in the literature. [1]
- In 1880s, Friedrich von Recklinghausen published seminal observations detailing cutaneous tumors comprised of both neuronal and fibroblastic tissue finally termed as neurofibromas.
- In 2006, Yang et al demonstrated a critical neurofibroma microenvironment interaction that includes SCF-stimulated Nf1+/− mast cells potentiating Nf1+/− fibroblast functions. [2]
References
- ↑ Morse RP (1999). "Neurofibromatosis type 1". Arch Neurol. 56 (3): 364–5. PMID 10190829.
- ↑ http://www.bloodjournal.org/content/116/2/157?sso-checked=true